Skip to main content
SpringerLink
Log in

Multipel myeloom

  • Chapter
  • First Online:
Ontwikkelingen in de oncologie

Part of the book series: Huisarts en Wetenschap ((HEW))

  • 1047 Accesses

Inleiding

Multipel myeloom of ziekte van Kahler is een kwaadaardige woekering van plasmacellen in met name het beenmerg. De aandoening maakt 1% uit van alle kwaadaardige aandoeningen en ongeveer 10% van de hematologische maligniteiten. In Nederland komen er jaarlijks ongeveer zevenhonderd nieuwe patiënten bij, met een gemiddelde leeftijd van 69 jaar – 5% van de patiënten is bij de diagnose jonger dan 40 jaar. Helaas verstrijkt er nog steeds veel tijd tussen het ontstaan van de klachten en het moment dat de diagnose gesteld is en de behandeling kan beginnen.1 Voor een deel ligt dit aan de patiënt zelf, maar ook bij de huisarts en de medisch specialist ontstaat de nodige vertraging.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 49.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatuur

  1. Van der Linden N, Uyl-de Groot CA, Wijermans PW. ‘Patient’s en doctor’s delay’ bij multipel myeloom en de ziekte van Waldenström. Nederlands Tijdschrift voor Hematologie 2010;7:218–23.

    Google Scholar 

  2. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21–33.

    Article  PubMed  Google Scholar 

  3. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives, risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121–7.

    Article  CAS  PubMed  Google Scholar 

  4. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749–57.

    Article  Google Scholar 

  5. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362–9.

    Article  CAS  PubMed  Google Scholar 

  6. Minnema MC, Van der Spek E, Van de Donk NW, Lokhorst HM. New developments in the treatment of patients with multiple myeloma. Neth J Med 2010;68:24–32.

    CAS  PubMed  Google Scholar 

  7. Van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2011;37:266–83.

    Article  CAS  PubMed  Google Scholar 

  8. Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): A double-blind, randomised controlled trial. Lancet Oncol 2010;11:973–82.

    Article  CAS  PubMed  Google Scholar 

  9. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Zweegman S, Lokhorst HM, Levin, M-D, de Waal E, Bos GM, Kersten MJ, et al. Richtlijnen behandeling multipel myeloom 2012. Nederlands Tijdschrift voor Hematologie 2012;9:300-320.

    Google Scholar 

  11. Lokhorst HM, Van der Holt B, Zweegman S, Vellenga E, Croockewit S, Van Oers MH, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 2010;115:1113–20.

    Article  CAS  PubMed  Google Scholar 

  12. Wijermans P, Schaafsma M, Termorshuizen F, Ammerlaan R, Wittebol S, Sinnige H, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study. J Clin Oncol 2010;28:3160–6.

    Article  CAS  PubMed  Google Scholar 

  13. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–17.

    Article  CAS  PubMed  Google Scholar 

  14. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010;28:2259–66.

    Article  CAS  PubMed  Google Scholar 

  15. Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 2001;28:607–12.

    Article  CAS  PubMed  Google Scholar 

  16. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: Therapeutic implications. Blood 2002;99:4525–30.

    Article  CAS  PubMed  Google Scholar 

  17. Van de Donk NW, Lokhorst HM, Bloem AC. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 2005;19:2177–85.

    Article  CAS  PubMed  Google Scholar 

  18. Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003;17:41–4.

    Article  CAS  PubMed  Google Scholar 

  19. Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 2010;24:22–32.

    Article  CAS  PubMed  Google Scholar 

  20. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–71.

    Article  CAS  PubMed  Google Scholar 

  21. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–42.

    Article  CAS  PubMed  Google Scholar 

  22. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–32.

    Article  CAS  PubMed  Google Scholar 

  23. Kneppers E, Lokhorst HM, Eeltink CM, Huls G, Kersten MJ, Koedam J, et al. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk 2010;10:138–43.

    Article  CAS  PubMed  Google Scholar 

  24. Van de Donk NW, Wittebol S, Minnema MC, Lokhorst HM. Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma. Br J Haematol 2010;148:335–7.

    Article  CAS  PubMed  Google Scholar 

  25. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: An open-label randomised controlled trial. Lancet Oncol 2010;11:29–37.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:4507–14.

    Article  CAS  PubMed  Google Scholar 

  27. Niesvizky R, Naib T, Christos PJ, Jayabalan D, Furst JR, Jalbrzikowski J, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: Adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007;138:640–3.

    Article  CAS  PubMed  Google Scholar 

  28. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San MJ, Barlogie B, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414–23.

    Article  CAS  PubMed  Google Scholar 

  29. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071–6.

    CAS  PubMed  Google Scholar 

  30. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 2003;101:2377–80.

    Article  CAS  PubMed  Google Scholar 

  31. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639–47.

    Article  CAS  PubMed  Google Scholar 

  32. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–98.

    Article  CAS  PubMed  Google Scholar 

  33. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557–60.

    Article  CAS  PubMed  Google Scholar 

  34. Sonneveld P, Van der Holt B, Schmidt-Wolf IGH, Bertsch U, Jarari Le, Salwender HJ, et al. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2008;112:653.

    Google Scholar 

  35. Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008;22:1485–93.

    Article  CAS  PubMed  Google Scholar 

  36. Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I, et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010;34:1395–7.

    Article  CAS  PubMed  Google Scholar 

  37. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113–20.

    Article  CAS  PubMed  Google Scholar 

  38. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008;26:4784–90.

    Article  CAS  PubMed  Google Scholar 

  39. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 2009;49:1211–25.

    Article  CAS  PubMed  Google Scholar 

  40. Kumar S, Blade J, Crowley J, Goldschmidt H, Hoering A, Jagannath S, et al. Natural history of multiple myeloma relapsing after therapy with IMiD’s and bortezomib: A multicenter International Myeloma Working Group study. Blood (ASH Annual Meeting Abstracts) 2009;114:2878.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. hematoloog, afdeling Hematologie, UMC Utrecht, Utrecht, Netherlands

    Niels van de Donk

  2. hematoloog, afdeling Interne Geneeskunde, Ziekenhuis Rijnstate, Arnhem, Arnhem, Netherlands

    Ellen van der Spek

Authors
  1. Niels van de Donk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ellen van der Spek
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Cuijk, The Netherlands

    Linda Bröker

  2. NHG, Domus Medica, Utrecht, The Netherlands

    Just Eekhof

Copyright information

© 2014 Bohn Stafleu van Loghum

About this chapter

Cite this chapter

van de Donk, N., van der Spek, E. (2014). Multipel myeloom. In: Bröker, L., Eekhof, J. (eds) Ontwikkelingen in de oncologie. Huisarts en Wetenschap. Bohn Stafleu van Loghum, Houten. https://doi.org/10.1007/978-90-368-0436-3_15

Download citation

  • DOI: https://doi.org/10.1007/978-90-368-0436-3_15

  • Published:

  • Publisher Name: Bohn Stafleu van Loghum, Houten

  • Print ISBN: 978-90-368-0435-6

  • Online ISBN: 978-90-368-0436-3

  • eBook Packages: Dutch language eBook collection

Publish with us

Policies and ethics

Search

Navigation